

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Rogers et al.

**Application No.** 10/533,414

**Filed:** April 29, 2005

**Confirmation No.** 4172

**For:** N-ACETYL-D-GLUCOSAMINE (NAG)  
SUPPLEMENTED FOOD PRODUCTS  
AND BEVERAGES

**FILED VIA EFS ON JUNE 14, 2007**

**Examiner:** Michael C. Henry

**Art Unit:** 1623

**Attorney Reference No.** 6682-66957-02

SUBMITTED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO**  
**37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 are several English-language documents. Enclosed is one English-language document. Applicants respectfully request the documents listed on the accompanying form PTO-1449 be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Submitted herewith is the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c).

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

A handwritten signature in cursive script, appearing to read 'Sheree Lynn Rybak', is written over a horizontal line.

Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	6682-66957-02
Application Number	10/533,414
Filing Date	April 29, 2005
First Named Inventor	Rogers
Art Unit	1623
Examiner Name	Michael C. Henry

## **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0115639 A2	08/22/2002	Fan et al.
		5,141,964	08/25/1992	Noel

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/01992 A1	01/11/2001	SCA LOHNHERSTELLUNGS AG and PHARMA BASE S.A.

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.